Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesPulmonary hypertension complicating congenital heart disease
Current Cardiology Reports, 07/08/09
Rame JE - The aim of disease management in this patient population should be to prevent or improve right heart failure. Current therapies that modify the progression of pulmonary vascular disease, including endothelin-1 receptor antagonists, phosphodiesterase-5 inhibitors, and prostanoids, should be considered carefully in patients with congenital heart disease-associated pulmonary hypertension. The risks and benefits of altering the balance of pulmonary vascular resistance to systemic vascular resistance must be weighed for each patient.
Today in CV/Thromboembolic...keeping you current
Receive free subspecialty "5-minute updates" via email
Vena cava filter occlusion and venous thromboembolism risk in persistently anticoagulated patients: A prospective, observational cohort study
Chest, 11/03/09
Pulmonary embolism in pregnancy
The Lancet - Early Online Publication, 11/03/09
The Use of Sildenafil in Persistent Pulmonary Hypertension of the Newborn
American Journal of Perinatology, 10/28/09
Sponsor
Article Search
Sponsor